Literature DB >> 12675502

Medical management of prolactin-secreting pituitary adenomas.

Mark E Molitch1.   

Abstract

Prolactinomas are a common cause of reproductive/sexual dysfunction. Once other causes of hyperprolactinemia have been excluded with a careful history and physical examination, routine chemistries, a pregnancy test and a TSH, imaging with MRI or CT will delineate the size and extent of the tumor. Medical therapy is the initial treatment of choice. When infertility is the primary indication for treatment, bromocriptine use has an extensive safety experience and is preferred. However, for other indications, cabergoline appears to be more efficacious and better tolerated. Transsphenoidal surgery remains an option, especially for patients with microadenomas, when medical therapy is ineffective.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12675502     DOI: 10.1023/a:1022375429083

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  106 in total

Review 1.  Antipsychotic drug-induced hyperprolactinemia: clinical implications.

Authors:  M E Molitch
Journal:  Endocr Pract       Date:  2000 Nov-Dec       Impact factor: 3.443

2.  Cabergoline in the long-term therapy of hyperprolactinemic disorders.

Authors:  C Ferrari; A Paracchi; A M Mattei; S de Vincentiis; A D'Alberton; P Crosignani
Journal:  Acta Endocrinol (Copenh)       Date:  1992-06

Review 3.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

4.  Late development of resistance to bromocriptine in a patient with macroprolactinoma.

Authors:  E Delgrange; J Crabbé; J Donckier
Journal:  Horm Res       Date:  1998

5.  Psychotic reactions during treatment of pituitary tumours with dopamine agonists.

Authors:  T H Turner; J C Cookson; J A Wass; P L Drury; P A Price; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-27

6.  Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Authors:  A Colao; A Di Sarno; F Sarnacchiaro; D Ferone; G Di Renzo; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-03       Impact factor: 5.958

7.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

Authors:  A Colao; A Di Sarno; M L Landi; S Cirillo; F Sarnacchiaro; G Facciolli; R Pivonello; M Cataldi; B Merola; L Annunziato; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

8.  Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone.

Authors:  D L Kleinberg; A E Boyd; S Wardlaw; A G Frantz; A George; N Bryan; S Hilal; J Greising; D Hamilton; T Seltzer; C J Sommers
Journal:  N Engl J Med       Date:  1983-09-22       Impact factor: 91.245

9.  The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.

Authors:  Mary P Gillam; Stewart Middler; Daniel J Freed; Mark E Molitch
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

10.  Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size.

Authors:  J F Bonneville; D Poulignot; F Cattin; M Couturier; E Mollet; J L Dietemann
Journal:  Radiology       Date:  1982-05       Impact factor: 11.105

View more
  20 in total

1.  Cognitive and perceptual disturbances in a young man.

Authors:  Janos Zahajszky; Davin K Quinn; Felicia A Smith; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro.

Authors:  Qi YE; Qiao-yan ZHANG; Cheng-jian ZHENG; Yang WANG; Lu-ping QIN
Journal:  Acta Pharmacol Sin       Date:  2010-11-01       Impact factor: 6.150

3.  Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells.

Authors:  Zhipeng Su; Xiaolong Jiang; Chengde Wang; Jie Liu; Yunxiang Chen; Qun Li; Jinsen Wu; Weiming Zheng; Qichuan Zhuge; Kunlin Jin; Zhebao Wu
Journal:  Endocrine       Date:  2012-06-09       Impact factor: 3.633

4.  The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.

Authors:  Yan Ting Liu; Fang Liu; Lei Cao; Li Xue; Wei Ting Gu; Yong Zhi Zheng; Hao Tang; Yu Wang; Hong Yao; Yong Zhang; Wan Qun Xie; Bo Han Ren; Zhuo Hui Xiao; Ying Jie Nie; Ronggui Hu; Zhe Bao Wu
Journal:  Acta Neuropathol       Date:  2020-06-22       Impact factor: 17.088

Review 5.  [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].

Authors:  A Schäffler
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

6.  A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas.

Authors:  B G Sant' Anna; N R C Musolino; M R Gadelha; C Marques; M Castro; P C L Elias; L Vilar; R Lyra; M R A Martins; A R P Quidute; J Abucham; D Nazato; H M Garmes; M L C Fontana; C L Boguszewski; C B Bueno; M A Czepielewski; E S Portes; V S Nunes-Nogueira; A Ribeiro-Oliveira; R P V Francisco; M D Bronstein; A Glezer
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

Review 7.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

8.  Medical treatment of Cushing's disease: Overview and recent findings.

Authors:  Stephanie Smooke Praw; Anthony P Heaney
Journal:  Int J Gen Med       Date:  2009-12-29

9.  Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.

Authors:  Lisa M Neff; Michelle Weil; Alan Cole; Thomas R Hedges; William Shucart; Donald Lawrence; Jay-Jiguang Zhu; Arthur S Tischler; Ronald M Lechan
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 10.  Rational design of competitive prolactin/growth hormone receptor antagonists.

Authors:  Estelle Tallet; Vincent Rouet; Jean-Baptiste Jomain; Paul A Kelly; Sophie Bernichtein; Vincent Goffin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.